Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H4N2O4 |
| Molecular Weight | 156.0963 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O\N=C/C1=CC=C(O1)[N+]([O-])=O
InChI
InChIKey=PTBKFATYSVLSSD-UTCJRWHESA-N
InChI=1S/C5H4N2O4/c8-6-3-4-1-2-5(11-4)7(9)10/h1-3,8H/b6-3-
Nifuroxime is anti-infective agent used in protozoal & fungal infections. The combination of furazolidone and nifuroxime in vaginal suppositories and vaginal insufflation powder was found to be an effective trichomonacidal compound. Nifuroxime was marketed under the brand name Nifurat, Nifurat consists of Attapulgite and Nifuroxime. Nifurat is an oral, nonabsorbed medication that is used in the management of diarrhea. It works by adsorbing (binding) large numbers of bacteria and toxins and reducing the loss of water. Nifurat reduces the number of bowel movements, improves the consistency of loose or watery stools, and relieves the gastrointestinal cramping that often is associated with diarrhea. Used for: Nifurat is used for the short-term treatment of diarrhea. Nifuroxime is proposed as a radiosensitizing agent with solid tumors.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL612884 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13573186 |
|||
Target ID: CHEMBL612348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16107157 |
680.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: http://www.gmedication.com/?s=nifurat |
Primary | Nifurat Approved UseNifurat is used for the short-term treatment of diarrhea. |
||
| Curative | MICOFUR Approved UseTrichomonas vaginitis Launch Date1957 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.375 % 2 times / day multiple, vaginal Recommended Dose: 0.375 %, 2 times / day Route: vaginal Route: multiple Dose: 0.375 %, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Other AEs: Urticaria... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Urticaria | 0.375 % 2 times / day multiple, vaginal Recommended Dose: 0.375 %, 2 times / day Route: vaginal Route: multiple Dose: 0.375 %, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13573186
The patient is instructed to insert a suppository
high into the vagina each morning and night.
Route of Administration:
Vaginal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4539385
Curator's Comment: The ability of nifuroxime to
sensitize hypoxic cells in spheroids of Chinese-hamster V79-171B lung cells was tested.
Maximal sensitization with only moderate toxicity was expected when
spheroids were exposed to a concentration of 1 mM nifuroxime for 2 hours .
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28394
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1002
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
100000083874
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
C073332
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
m7890
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | Merck Index | ||
|
C77053
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
465N7P5U85
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
3381
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
DTXSID8046402
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
CHEMBL15721
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
662
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
6236-05-1
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
SUB09272MIG
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
228-349-6
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY | |||
|
5373493
Created by
admin on Mon Mar 31 17:50:35 GMT 2025 , Edited by admin on Mon Mar 31 17:50:35 GMT 2025
|
PRIMARY |
ACTIVE MOIETY